Lisa Carey on Minimizing Interventions for Breast Cancer Treatment
Lisa Carey, MD, professor of medicine, University of North Carolina at Chapel Hill, discusses the need to minimize interventions for breast cancer treatment.
Lisa Carey, MD, professor of medicine, University of North Carolina at Chapel Hill, discusses the need to minimize interventions for breast cancer treatment.
Breast cancer mortality has fallen by about 1/3 over the last couple of decades, Carey says. However, many patients are being overtreated due to the increase in therapy options across all treatment disciplines, including surgical, radiation, and medication.
Carey says that due to associated toxicities, treatment should be tailored to those who need it most and minimized for patients with less aggressive disease.
FDA Grants Accelerated Approval to Fam-Trastuzumab Deruxtecan-Nxki in HER2+ Solid Tumors
April 5th 2024The FDA granted accelerated approval to fam-trastuzumab deruxtecan-nxki (Enhertu) for patients with unresectable or metastatic HER2-positive solid tumors who have received prior systemic treatment.
Nurse Practitioners Weigh in on Data From the San Antonio Breast Cancer Symposium
January 16th 2023Loyda Braithwaite, MSN, RN, AGPCNP-BC, AOCNP; and Jamie Carroll, APRN, CNP, MSN, highlight presentations from the 2022 San Antonio Breast Cancer Symposium that will influence oncology nursing practice.
